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Background: The Adverse Event Reporting System (AERS) is an FDA database providing rich information on
voluntary reports of adverse drug events (ADEs). Normalizing data in the AERS would improve the mining capacity
of the AERS for drug safety signal detection and promote semantic interoperability between the AERS and other
data sources. In this study, we normalize the AERS and build a publicly available normalized ADE data source. The
drug information in the AERS is normalized to RxNorm, a standard terminology source for medication, using a
natural language processing medication extraction tool, MedEx. Drug class information is then obtained from the
National Drug File-Reference Terminology (NDF-RT) using a greedy algorithm. Adverse events are aggregated
through mapping with the Preferred Term (PT) and System Organ Class (SOC) codes of Medical Dictionary for
Regulatory Activities (MedDRA). The performance of MedEx-based annotation was evaluated and case studies were
performed to demonstrate the usefulness of our approaches.
Results: Our study yields an aggregated knowledge-enhanced AERS data mining set (AERS-DM). In total, the
AERS-DM contains 37,029,228 Drug-ADE records. Seventy-one percent (10,221/14,490) of normalized drug concepts
in the AERS were classified to 9 classes in NDF-RT. The number of unique pairs is 4,639,613 between RxNorm
concepts and MedDRA Preferred Term (PT) codes and 205,725 between RxNorm concepts and SOC codes after
ADE aggregation.
Conclusions: We have built an open-source Drug-ADE knowledge resource with data being normalized and
aggregated using standard biomedical ontologies. The data resource has the potential to assist the mining of ADE
from AERS for the data mining research community.Introduction
Since the early 1990s, adverse drug events (ADEs) have
received considerable attention from researchers in qual-
ity and patient safety [1]. Although randomized clinical
trials (RCTs) are considered as a gold standard for deter-
mining the safety issues of drugs, it is generally recog-
nized that premarketing RCTs may not detect all safety
issues related to a particular drug in clinical practice [2].
The US Food and Drug Administration (FDA) Adverse
Event Reporting System (AERS) is one of the main re-
sources in post-marketed ADE detection based on data
mining techniques [3,4]. The main data mining metrics
used for ADE detection include the proportional report-
ing ratio (PRR), the reporting odds ratio (ROR), the in-
formation component (IC), and the empirical Bayes
geometric mean (EBGM) [5]. For example, Kadoyama* Correspondence: wlw@jlu.edu.cn
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reproduction in any medium, provided the oret al. [6] used the above metrics and detected signals for
paclitaxel-associated mild, severe, and lethal hypersensi-
tivity reactions and docetaxel-associated lethal reactions.
Poluzzi et al. [7] detected drug-induced torsades de
pointes (TdP) signals of linezolid, caspofungin, posaco-
nazole, indinavir, and nelfinavir using ROR. However,
most of existing studies on the AERS were carried out
for a small number of drugs [6,8-10], and few studies
were focused on large-scale mining or on detecting the
etiology of ADE signals in terms of mechanism of action,
physiologic effect, or molecular structure of drugs [11].
We realize that potential of the AERS has not been fully
utilized, and one of main reasons for this is because
there is a lack of standardization among drug names.
In the AERS, drugs can be registered by arbitrary names,
including trade names, abbreviations, and even typograph-
ical errors since they are directly entered by health care
professionals (e.g., physicians, pharmacists, nurses, etc.) and
consumers (e.g., patients, family members, lawyers, etc.)
[5]. There is limited normalization effort for the AERS data.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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names, if available, based on sources such as the Orange
Book [12] and other internal databases [13]. Otherwise,
the verbatim names are used, thus forming substantial
barriers for data integration for the purpose of ADE signal
detection. There have been some attempts in drug name
normalization when mining AERS, but typically it is either
unclear how the normalization was conducted or the
normalization was attempted only for a small number of
drugs [3,6,9-11,14-16].
In terms of ADE names, AERS does provide normal-
ized terms based on Medical Dictionary for Regulatory
Activities (MedDRA) preferred terms (PTs), though the
use of MedDRA requires a license. In this study, we have
demonstrated that MedDRA PT-based normalization ac-
tually enables the powerful data aggregation capability
when we link the PT terms to their corresponding
System Organ Class (SOC) categories.
In this study, we aim to produce an open-source AERS
data mining set (AERS-DM), which is normalized and
aggregated with two standard drug ontologies, including
RxNorm and the National Drug File-Reference Termin-
ology (NDF-RT), and one ADE terminology, MedDRA.
Methods
Resources
The FDA AERS database is a public database that in-
cludes 7 tables. Its structure is in compliance with the
international safety reporting guidance (ICH E2B) [17].
Information related to a single AERS report can be re-
trieved from those tables using a unique identifier (i.e.,
Individual Safety Report (ISR) number). Among them,
the DRUG table includes drug-related information such
as “DRUG_SEQ” (a unique number for identifying a
drug in a report), “DRUGNAME,” “ROUTE” (the route
of drug administration), and “DOSE_VBM” (verbatim
text for dose, frequency, and route, exactly as entered on
the report). The REAC table includes adverse event in-
formation using PTs in MedDRA, a medical terminology
adopted to describe adverse drug event [18]. The DEMO
table includes patient demographics and administrative
information of the events, including “CASE” (case num-
ber for identifying an AERS case) and “FDA_DT” (date
FDA received report).
RxNorm, released initially in 2004, is a standardized no-
menclature for clinical drugs and drug delivery devices
[19]. Since its creation, RxNorm has been increasingly rec-
ognized by the biomedical informatics community as an
emerging standard for clinical information exchange [20].
RxNorm is organized by concepts, in which each concept
consists of drug names sharing the same meaning at a spe-
cific level of abstraction and is assigned a concept unique
identifier (RxCUI). RxNorm also provides relationships
between concepts, as indicated in Figure 1, adapted fromPeters and Bodenreider [21]. For example, 'Diphenhydra-
mine Hydrochloride’ is the precise_ingredient_of ‘Tylenol
PM’. The description of all such relationships can be re-
trieved, see the Availability and requirements section for
the webpage. Data in RxNorm is distributed in Rich Re-
lease Format (RRF) tables, which is the default relational
format used by the National Library of Medicine (NLM).
NDF-RT was developed by the Veterans Health Admin-
istration, providing clinical information about medications,
and has been included in RxNorm. NDF-RT uses a de-
scription logic-based, formal reference model that groups
drugs and ingredients into the high-level classes for Chem-
ical Structure (e.g., Acetanilides), Mechanism of Action
(e.g., Prostaglandin Receptor Antagonists), Physiological
Effect (e.g., Decreased Prostaglandin Production), drug-
disease relationship describing the Therapeutic Intent (e.g.,
Pain), Pharmacokinetics describing the mechanisms of ab-
sorption and distribution of an administered drug within a
body (e.g., Hepatic Metabolism), and legacy VA-NDF clas-
ses for Pharmaceutical Preparations (VA Drug Class; e.g.,
Non-Opioid Analgesic) [22]. Figure 2 shows the NDF-RT
content model [23] together with an example showing drug
class information for BUTABARBTIAL NA 100MG CAP.
We utilized RxNorm and NDF-RT for normalizing
and aggregating drug information in AERS in consider-
ation of three reasons. First, these two ontologies are
publicly available medication ontologies that have been
intensively developed and used for drug data integration
[22,24,25]. Second, RxNorm aims to enable various sys-
tems using different standardized drug nomenclatures to
share and exchange data efficiently, which we believe
meets the requirements for meaningful use of the ADE
reporting data. In addition, since RxNorm only repre-
sents a nomenclature of drugs and does not contain
drug categorical information, we leveraged the categor-
ical information extracted from NDF-RT for medication
data aggregation. Third, as a part of the Unified Medical
Language System (UMLS), RxNorm and NDF-RT can
function as interoperable drug standards that can inte-
grate with other health data, such as electronic health
records (EHRs), so as to facilitate the semantic integra-
tion of the data in the health domain.
Finally MedDRA is a controlled terminology devel-
oped for reporting adverse events, related to drugs, to
regulatory agencies [26]. MedDRA has a hierarchical
structure with five levels: SOC, High-Level Group Term
(HGLT), High-Level Term (HLT), PT and Lowest-Level
Term (LLT). There are 26 classes (SOCs). PTs are the
main descriptors in MedDRA and are used in AERS. All
MedDRA terms are integrated UMLS.
Tool
In our study, we used a natural language processing
(NLP) tool, MedEx, to normalize AERS drugs. MedEx
Figure 1 Relations among RxNorm concepts, adapted from Peters and Bodenreider [21].
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Besides MedEx, there are a number of other existing
NLP-based tools available that could be used for drug
normalization, including MedLEE [28], National Center
for Biomedical Ontology (NCBO) Annotator Web Service
[29], and Mayo cTAKES [30]. We chose to use the MedEx
because we consider it an optimized system for drug
normalization with a relative good performance, ranked
second in the 2009 i2b2 Medication Extraction challenge,
where the first-place system in that challenge is not
available for public use [31]. The evaluation showed that
MedEx performed well on identifying drug names, with
precision (97%), recall (88%) and F-measure (92%) for 50
discharge summaries and precision (95%), recall (92%)
and F-measure (93%) for 25 clinic notes, respectively [27].In this study, we used MedEx version 2.0. Input files for
MedEx included concrete information on drugs, and out-
put normalized data included RxNorm codes.
Data processing
Figure 3 presents an overview of the data processing flow
that contains three steps: de-duplication, drug normalization,
and data aggregation. In the de-duplication step, redundant
reports are removed. In the normalization step, MedEx is
applied to normalize AERS drugs to RxNorm codes. During
aggregation, adverse events are aggregated according to
MedDRA SOC and PT codes, and NDF-RT–based classi-
fication information for those drugs is obtained from
RxNorm. Two tables are formed; one stores the normalized
Drug-ADE information and the other stores the aggregated
Figure 2 NDF-RT content model and the example. Triangles denote hierarchies of related concepts, categorized in the rectangles within the
triangles. Taxonomic or ISA relationships (upward-pointing blue solid arrows) unify NDF-RT™ clinical drug concepts into a polyhierarchy, classified
both by their VA drug class and their generic ingredient(s). Various named role relationships (sideways-pointing amber dash arrows) define the
central drug concepts (green) from which they originate in terms of the reference hierarchy concepts (blue) pointed to. Role relationships are also
inherited into subsumed clinical drug concepts. Adapted from NDF-RT document [April 2012 Version] [23].
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be connected through the RxNorm codes. Those steps are
further detailed below.
Removing redundant AERS data
According to the FDA’s recommended method for de-
duplication, for reports with the same CASE number,
we select the latest (most recent) report date (i.e.,
FDA_DT) in the AERS “DEMO” table. For reports with
the same CASE and FDA_DT values, we select the one
with the highest ISR number. Table 1 shows examples
of how to delete duplicate reports. We select the ISR
“4275741” for CASE number “4047837,” and ISR
“7637797” for CASE number “8468457.” Consequently,Figure 3 An overview of the data processing flow.the selected ISRs in the DEMO table are kept in DRUG
and REAC tables.
Normalizing AERS drug and ADE data
After de-duplication, we concatenate the following fields
in the DRUG table: “DRUGNAME,” “ROUTE,” and
“DOSE_VBM, and the resulting strings are normalized
with MedEx. Compared to DRUGNAME alone, the
concatenated string gives more comprehensive informa-
tion about the corresponding drug, since the “ROUTE”
field can provide information such as “Oral” and the
“DOSE_VBM” field can provide information such as
“Tablet.” The results are mapped to the RxNorm code
RxCUI. For example, the concatenated string “POTASSIUM
Table 1 Examples of duplicate reports
ISR CASE FDA_DT De-duplication
4269368 4047837 20040113 ×
4275741 4047837 20040121 √
7637789 8468457 20110720 ×
7637797 8468457 20110720 √
“ISR” is the unique number for identifying an AERS report. “CASE” is the
number for identifying an AERS case. "FDA_DT” is the date FDA received
report. “De-duplication” indicates the positive or negative action.
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RELEASE TABLET ORAL 20 MEQ BID ORAL” is nor-
malized to RxCUI 198116 (i.e., “Potassium Chloride 20
MEQ Extended Release Tablet”). Meanwhile, we map
“PT” entries of the REAC table to PT and SOC codes of
MedDRA.
Aggregating normalized drug and ADE data
The algorithm for classifying AERS drugs based on NDF-
RT includes two parts; the first part is to identify the cor-
responding NDF-RT concepts for those normalized AERSFigure 4 Traversal pathways for classifying AERS drugs based on NDFdrugs and the second is to extract the associated NDF-RT
classification information.
Specifically, RxNorm contains NDF-RT ingredients and
clinical drugs. Meanwhile, NDF-RT ingredients are con-
nected to their mechanisms of action, physiologic effects,
and therapeutics (indications and contraindications) and
the corresponding clinical drugs inherit those relations.
NDF-RT clinical drugs are also connected to their corre-
sponding VA drug classes. Therefore, if a given RxCUI
itself is an NDF-RT concept (i.e., one of its sources is
NDF-RT), we use it to find NDF-RT classification infor-
mation. Otherwise, we traverse the relations provided by
RxNorm to greedily identify the related NDF-RT ingredi-
ents and clinical drugs, and then extract the associated
classification information (see Figure 4).
We obtain PT and SOC codes in MedDRA for “PT” en-
tries in the AERS. For example, “PT” entries “Anaemia of
chronic disease,” “Anaemia of malignant disease,” and
“Nephrogenic anaemia” are mapped to corresponding PT
codes “10002073,” “10049105,” and “10058116.” And these
codes are aggregated under the SOC code “10005329”
(i.e., “blood and lymphatic system disorders”).-RT.
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For the experiments, we first gathered the AERS data that
are publicly available from 2004 to 2011 [32]. We used the
May 2012 release of RxNorm (which contains the map-
pings to NDF-RT) and the 14.1 version of MedDRA. We
ultimately produced an AERS-DM that is composed of
two tables, one containing the normalized Drug-ADE in-
formation and the other containing the aggregation infor-
mation of the Drug-ADEs. We then analyzed the statistics
of the normalization and aggregation for AERS data in the
AERS-DM. We also performed case studies to demon-
strate the usefulness of the AERS-DM.
We evaluated the normalization performance of MedEx
in two steps. For the first step, we randomly selected 200
unique input drug names before MedEx-based annota-
tions. We recruited three reviewers with medical back-
ground who manually reviewed the 200 drug names and
annotated them using the RxNorm codes. The version of
the RxNorm used in the evaluation was the same as that
included in MedEx. A gold standard was generated after
the reviewers achieved inter-agreements. Precision (P), Re-
call (R), and F-measure (F) were calculated for these se-
lected drug names, using P = TP/(TP + FP), R = TP/(TP +
FN), and F = 2PR/(P + R), in which TP stands for True
Positive, FP stands for False Positive, and FN stands for
False Negative. For the second step, we randomly selected
100 drug names that failed to be normalized. Then we
confirmed whether or not the drug names are included in
RxNorm. In addition, we checked to see if an unmatched
drug name is a valid domestic or foreign drug by using
two drug resources. The first resource is Drugs@FDA, a
drug dictionary providing FDA-approved brand and gen-
eric drug information [13], and the second resource is
Drugs.com, the largest independent drug information
website available on the Internet [33].
Additionally, we evaluated the validity of the algorithm
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Figure 5 Distribution of unique drug names in AERS.and NDF-RT concepts. We randomly selected 20 AERS
drug names and manually checked the accuracy of the
mappings produced by our algorithms.
Results
General statistics of normalization and aggregation
After de-duplicating reports, according to the recom-
mended method in the download files provided by FDA
[34], the number of AERS records is reduced to 2,643,979
from the original 3,874,965. The number of unique “verba-
tim” drug names is reduced to 1,517,811 from the original
1,700,925.
For drug name normalization, 1,125,045 of 1,517,811
(74%) AERS unique drug names were normalized to
14,489 unique RxNorm concepts, of which 10,221 (71%)
were classified in NDF-RT.
For the ADE normalization, we mapped 14,740 existing
MedDRA PT terms in the AERS to MedDRA codes, ac-
counting for 76% of 19,294 total MedDRA PT terms.
These MedDRA PT codes were then mapped to 26 Med-
DRA SOCs.
Figure 5 shows the distribution of unique drug names in
the AERS (normalized with the single field “DRUGNAME”),
which follows Zifp’s Law. In other words, the more popu-
lar the drug names are, the higher the chance those drug
names are to be normalized by the RxNorm codes.
We classified the RxNorm concepts using the NDF-RT.
Table 2 shows the coverage of AERS drugs by NDF-RT
classes. For example, 5,823 RxNorm concepts were mapped
to 29 corresponding VA classes, accounting for 57% of all
classified RxNorm concepts and corresponding to 77% of
total AERS reports. Table 3 shows the results of MedDRA
PTcode aggregation by MedDRA SOCs.
Statistics of AERS-DM
The AERS-DM includes two tables, as discussed above.
There are 37,029,228 Drug-ADE records after de-10 15 20
og2) of unique drug name in AERS
Table 2 Coverage of AERS drugs by NDF-RT classes
Drug_class_type1 Drug_class, No.2 RxNormConcept, No. in the AERS3 a%4 b%5
Generic Ingredient Combinations 26 9,813 96 88
Chemical Ingredients Class 16 9,331 91 81
Therapeutic Intent 24 8,069 79 78
Mechanism of Action 7 8,061 79 81
Physiologic Effect 16 7,989 78 82
VA Class 29 5,823 57 77
FDA Established Pharmacologic Class (EPC) 66 3,049 30 46
Therapeutic Category 7 2,880 28 50
Pharmacokinetics 1 730 7 28
Total 192 10,221 100 100
1“Drug_class_type” represents various classes provided by NDF-RT as shown in Figure 2.
2“Drug_Class, No.” is the number of direct subordinate classes of each Drug_class_type.
3“RxNorm concept, No. in the AERS” shows the total number of RxNorm concepts in the AERS for each drug class type.
4“a%” indicates the percentage of classified RxNorm concepts for each Drug_class_type, calculated as the division of “RxNorm concept, No. in the AERS” by
10,221; a total of RxNorm concepts mapped to at least one NDF-RT class.
5“b%” indicates the percentage of classified AERS reports, calculated as the division of the number of AERS reports assigned with the Drug_class_type by the total
AERS report number (2,643,979).
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concepts and MedDRA codes is 4,639,613, and between
RxNorm concepts and SOC pairs after ADE aggregation,
205,725. Tables 4 and 5 show the top 10 most frequent
pairs (Therapeutic Category, PT and Therapeutic Category,
SOC), respectively.Evaluation results
The initial inter-annotator agreement on the 200 anno-
tated drug names was 62.8%, a low agreement rate, maybe
due to the various understandings in the rules for drug
name normalization from the annotation training. It in-
deed indicated the difficulty of the drug normalization in
AERS. Comparing MedEx-based annotations with the
gold standard generated from majority votes by three hu-
man reviewers, we calculated the performance measures.
TP, FP and FN were calculated as 138, 7 and 6 respect-
ively. Recall, Precision and F-measure were then calculated
as 95.8%, 95.2% and 95.5% respectively, which is compar-
able with performance measures in the original evaluation
of MedEx [27]. The slight difference may be caused by dif-
ferent evaluation contexts, and different drug name num-
bers in gold standards, with discharge summaries (377),
clinic notes (200) and AERS (200). The false positive was
low in the 200 annotated drug names, which was mainly
due to the false recognition of partial drug names, for ex-
ample, both drug names “ADONA (CARBAZOCROME
SODIUM SULFONATE)” and “CLEXANE (HEPARNI-
FRACTION SODIUM SALT)” were normalized to “so-
dium (RxCUI 9853)”. The first, a foreign drug from Italy
and Japan, is out of the scope of RxNorm, the second is
covered by RxNorm but not identified. As a result both
are falsely mapped by MedEx.Table 6 shows the evaluation results of 100 drug
names failed to be normalized by MedEx. A large por-
tion of them (75) are due to problems associated with
AERS records, including names not covered by RxNorm
such as foreign drug names, typographical errors, un-
specified names (e.g., BLINDED PLACEBO), herbs (e.g.,
ALOEELITE), domestic drugs (e.g., PANHEPRIN), new
drugs (e.g., HIZENTRA, approved by the FDA in 2010),
and non-drugs (e.g., RADIATION THERAPY). A small
portion of them (25) that failed to be mapped are due to
MedEx. The evaluation results revealed several issues
related to drug name normalization. First, the public re-
lease of MedEx (version 2.0) is in an executable format,
which prevents the use of the latest version of RxNorm
for drug name normalization. For example, the drug
name “SAPHRIS” did not have a match using MedEx
because it is included in RxNorm in the 2012 version
but not in the 2008 version (used in MedEx). Second,
RxNorm does not contain foreign brand names since it is
intended to cover drugs prescribed in the United States.
Third, we found that some of the records in AERS contain
unspecified names. An example is the name “BLINDED
PLACEBO,” which is used as a drug name and makes the
normalization infeasible. We would suggest that incorpor-
ating thorough normalization at the point of data entry is
desired, so as to improve the data quality for data mining.
Manual evaluation shows the greedy algorithm used to
find mapping between RxNorm and NDF-RT is 100% valid.
Case studies for AERS-DM
As described in the section above, the study produced an
AERS-DM containing normalized and aggregated AERS
reporting data. To demonstrate the usefulness of the
AERS-DM, we used the AERS-DM to analyze the NDF-
Table 3 Aggregation of MedDRA PT codes by MedDRA SOCs
MedDRA SOC Code MedDRA SOC Terms PT Codes, No.1 AERS Reports, No. (%)2
10018065 General disorders and administration site conditions 595 875,070 (15.6)
10029205 Nervous system disorders 729 570,448 (10.2)
10017947 Gastrointestinal disorders 699 447,243 (8.0)
10022891 Investigations 2,748 407,270 (7.3)
10037175 Psychiatric disorders 453 329,198 (5.9)
10022117 Injury, poisoning, and procedural complications 697 311,952 (5.5)
10038738 Respiratory, thoracic, and mediastinal disorders 437 287,425 (5.1)
10028395 Musculoskeletal and connective tissue disorders 365 276,784 (4.9)
10040785 Skin and subcutaneous tissue disorders 390 273,674 (4.9)
10021881 Infections and infestations 1,361 267,741 (4.8)
Infections and infestations
10007541 Cardiac disorders 283 237,037 (4.2)
10047065 Vascular disorders 595 195,591 (3.5)
10027433 Metabolism and nutrition disorders 236 160,134 (2.9)
10038359 Renal and urinary disorders 288 132,055 (2.4)
10029104 Neoplasms benign, malignant and unspecified (incl. cysts and polyps) 1,293 129,227 (2.3)
10005329 Blood and lymphatic system disorders 218 122,276 (2.2)
10015919 Eye disorders 462 114,312 (2.0)
10042613 Surgical and medical procedures 1,176 89,005 (1.6)
10019805 Hepatobiliary disorders 162 79,067 (1.4)
10038604 Reproductive system and breast disorders 381 73,431 (1.3)
10021428 Immune system disorders 111 64,127 (1.1)
10041244 Social circumstances 189 48,077 (0.9)
10036585 Pregnancy, puerperium and perinatal conditions 182 36,959 (0.7)
10013993 Ear and labyrinth disorders 75 30,174 (0.5)
10010331 Congenital, familial, and genetic disorders 833 21,244 (0.4)
10014698 Endocrine disorders 129 18,053 (0.3)
1“PT Codes, No.” shows the number of PT codes for each SOC.
2“AERS Reports, No. (%)” shows the number of AERS reports and the percentage among the overall AERS report number for each SOC, where one report may
contain several SOCs associated with several drugs.
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ing ADE categories represented by the MedDRA SOCs.
Specifically, we joined the two tables in the AERS-DM
and retrieved the AERS reports under seven existing
pharmacokinetics classes. We then analyzed the data,
including their corresponding MedDRA SOC-based
ADE categories.
Figure 6 shows a profile of seven pharmacokinetics
classes in the AERS-DM. The bars represent the total
number of AERS reports for each individual pharmaco-
kinetics class and the line represents the total drug num-
bers under each pharmacokinetics class. This figure
illustrates that most drugs with pharmacokinetics class
information reported in the AERS are relevant to “Renal
Excretion” and “Hepatic Metabolism.” We also found
that the number of AERS reports is disproportional tothe number of drugs for some pharmacokinetics classes.
For example, the class “Hepatic excretion” contains
fewer drugs than the class “Fecal excretion” but has
more AERS reports. The result indicates that the drugs
in the “Hepatic excretion” class may be associated with
more AERS reports than the “Fecal excretion” class, and
interesting etiology knowledge may be found through
further mining with disproportionality metrics and other
data sources, including EHRs.
Figure 7 shows a profile of 26 MedDRA SOC-based
ADE categories that corresponds to the seven pharma-
cokinetics classes in the AERS. The bars represent the
total number of AERS reports for each individual SOC
and the line represents the total number of drugs associ-
ated with each SOC category. The figure illustrates that
the top five most frequent ADE categories are “General
Table 4 Therapeutic category and PT pairs
Co-occurrence, No. Therapeutic Category, Codes (Terms) PT, Codes (Terms)
31,858 2225 (Central Nervous System Agent) 10028813 (Nausea)
30,824 2225 (Central Nervous System Agent) 10013709 (Drug ineffective)
24,922 882 (Antirheumatic Agent) 10022086 (Injection site pain)
23,633 882 (Antirheumatic Agent) 10028596(Myocardial infarction)
20,240 2095 (Cardiovascular Agent) 10028813 (Nausea)
18,435 2095 (Cardiovascular Agent) 10013968 (Dyspnoea)
15,695 4703 (Gastrointestinal Agent) 10028813 (Nausea)
11,709 4703 (Gastrointestinal Agent) 10012735 (Diarrhoea)
10,509 884 (Anti-infective Agent) 10028813(Nausea)
10,505 884 (Anti-infective Agent) 10037660 (Pyrexia)
10,022 988 (Antineoplastic Agent) 10012735 (Diarrhoea)
8,865 988 (Antineoplastic Agent) 10011906 (Death)
100 106571 (Diagnostic Agent) 10022061(Injection site erythema )
69 106571 (Diagnostic Agent) 10028813(Nausea)
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system disorders,” “Gastrointestinal disorders,” “Investi-
gations,” and “Respiratory, thoracic, and mediastinal dis-
orders.” Similarly, we found that the number of AERS
reports is disproportional to the number of drugs for
some MedDRA SOC categories. The result may reveal
some important areas of ADE surveillance for post-
marketing drugs if combined with prescription informa-
tion as the denominator.
Discussion
In addition to the significance described in the Introduction
section above, the present study was also partially moti-
vated by our previous work on building a standardizedTable 5 Therapeutic category and SOC pairs
Co-occurrence, No. Therapeutic Category, Codes (Terms)
133,936 2095 (Cardiovascular Agent)
90,959 2095 (Cardiovascular Agent)
194,311 2225 (Central Nervous System Agent)
175,172 2225 (Central Nervous System Agent)
129,953 882 (Antirheumatic Agent)
61,386 882 (Antirheumatic Agent)
76,007 4703 (Gastrointestinal Agent)
69,825 4703 (Gastrointestinal Agent)
65,105 884 (Anti-infective agent)
41,900 884 (Anti-infective agent)
53,478 988 (Antineoplastic Agent)
35,625 988 (Antineoplastic Agent)
403 106571 (Diagnostic Agent)
251 106571 (Diagnostic Agent)knowledge base of ADEs known as ADEpedia, in which
we intended to integrate and normalize known ADE
knowledge from disparate ADE datasets (e.g., the FDA
structured product labels, and the UMLS) [35,36]. We
consider that the FDA AERS reporting database is
another important data source for ADE knowledge
discovery and the normalization of both the drug and
ADE names is the first important task we need to tackle
with.
Drug and ADE aggregation
NDF-RT is a major national source of drug classification
information, providing multi-axial classifications such as
physiological effect, mechanism of action, etc. It has provedSOC, Codes (Terms)
10018065 (General disorders and administration site conditions)
10029205 (Nervous system disorders)
10018065 (General disorders and administration site conditions)
10029205 (Nervous system disorders)
10018065 (General disorders and administration site conditions)
10029205 (Nervous system disorders)
10018065 (General disorders and administration site conditions)
10017947 (Gastrointestinal disorders)
10018065 (General disorders and administration site conditions)
10029205 (Nervous system disorders)
10018065 (General disorders and administration site conditions)
10017947 (Gastrointestinal disorders)
10018065 (General disorders and administration site conditions)
10040785 (Skin and subcutaneous tissue disorders))
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http://www.jbiomedsem.com/content/5/1/36to be capable of representing medications in clinical set-
tings. For example, Rosenbloom et al. [37] investigated the
coverage of the Physiologic Effects hierarchy in NDF-RT
and found this category to be sufficient for classifying med-
ications. Zhu et al. [38] used the FDA Established Pharma-
cologic Class in NDF-RT to profile Structured Product
Labelling for clinical applications.
On the other hand, the applicability of NDF-RT and
RxNorm for clinical drug classification was explored, and
the imperfect mappings between RxNorm and NDF-RT
and incomplete drug classification were evidenced by sev-
eral studies [22,24,25]. Palchuk et al. [25] used the NDF-
RT’s drug class tree to organize RxNorm into a hierarchy
and evaluated this mapping using data from EHRs. Pathak
et al. [22] investigated the applicability of RxNorm and
NDF-RT for representation and classification of medica-
tion data from EHRs using the NLM’s NDF-RT web ser-
vices API for NDF-RT drug class assignment. Both of the
above studies were limited to the “Drug Products by VA











Figure 6 A profile of pharmacokinetics classes in AERS.with no consideration of the multi-axial hierarchies. In
addition, issues in mapping and classifying drugs from
RxNorm using the NDF-RT’s multi-axial classification
were investigated by Pathak and Chute [24]. In the study,
they identified the issues in NDF-RT, including the lack
of coverage of drug classes (chemical structure, mech-
anism of action, physiologic effect, therapeutic intent,
and pharmacokinetics) for clinical drugs, and suggested
that the resolution would rely on the targeted improve-
ment of NDF-RT. Thus, the existing studies on the clas-
sification of RxNorm using NDF-RT are either about
multi-axial classification, based on the mapping be-
tween the two ontologies, or limited to VA class based
on EHR data.
In the context of standardizing the AERS data in this
study, we developed a systematic algorithm in which the
rich semantic connections within RxNorm were fully
utilized to build the mappings with the related concepts
in NDF-RT. The mappings were then used to aggregate
the AERS data under multi-axial classifications in NDF-
RT. Different from those related studies, the present
study focuses on real-world data in the AERS and pre-
sents a normalized AERS-DM data set together with all
corresponding drug classification information provided
by NDF-RT for large-scale data mining purposes. The
evaluation results show that the greedy algorithm for
maximum mapping to corresponding NDF-RT concepts
from RxNorm codes was valid. We believe that the map-
ping method developed in our study could be useful in
other similar context.
We found that the MedDRA PT terms coding ADEs
in the AERS changed over time. The used AERS data
ranged from 2004 to 2011, and during that time period
the MedDRA versions had been updated twice annually
[39]. Some ADE codes in the AERS from the older Med-










Figure 7 A profile of MedDRA SOC for pharmacokinetics classes in AERS.
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http://www.jbiomedsem.com/content/5/1/36identification of Drug-ADE pairs. In the future, we will
consider whether making the PT terms consistent over
the years before conducting ADE detection (i.e., building
a version control mechanism) may be useful for improv-
ing data quality.
In addition, other studies have identified a number of
issues related to the use of MedDRA. For example, the
hierarchy problems and semantic reasoning incapability
of MedDRA mitigate its usefulness for querying and
analyzing AERS data. SNOMED-CT, as the largest clin-
ical terminology, can complement these disadvantages,
with as many levels of hierarchy as are considered ap-
propriate, and the semantic consistency in relationships
[40]. In addition, using SNOMED-CT for ADE coding
can also achieve the integration of ADE data in the
AERS with other health data sources, including EHRs. A
few studies have demonstrated the mappings between
MedDRA and SNOMED-CT. For example, Bodenreider
[41] proposed the mappings by leveraging the structure
of SNOMED-CT for aggregation purposes. Mougin et al.
[42] proposed to improve the mapping through an auto-
matic lexical-based approach. A recent study [43] com-
pared three methods using the Ontology of Adverse
Events (OAE), MedDRA, and SNOMED-CT in classify-
ing the ADE terms associated with two vaccines. Among
the three methods,, the OAE method provided better
classification results. This initiative is inspiring in the
field of ADE detection for vaccines. However, given that
it is a newly emerging ontology with only 2723 terms,
the coverage of the OAE is very limited. For the AERSdata normalization and aggregation, we consider that the
widely used SNOMED-CT would be a better candidate as
an ADE terminology, and this will be one of our future
works.
Case studies
We demonstrated the usefulness of the AERS-DM pro-
duced by this study by analyzing the data set using the
pharmacokinetics class. There are other class dimen-
sions available for analysis, including physiologic effect,
mechanism of action, and VA class, all of which come
from the knowledge structure asserted in the NDF-RT.
We believe that the knowledge asserted in the standard
ontologies will enrich the AERS-DM and enable the
meaningful use of AERS data for ADE signal detection
and data mining.
Implication of study
Based on AERS-DM, more efficient data mining and ADE
detection in individual drugs would be achieved and facili-
tated. The reasons are three-fold as follows. First, having
enriched features of drugs and enlarged cohort informa-
tion, AERS-DM could provide potential explanations for
individual differences in ADEs. Second, with the capability
of large-scale ADE mining, comparative analysis of differ-
ent drug classes could be explored, thus accumulating
ADE evidence in the field of individual drugs. Third, pre-
senting more meaningful organization of drug and ADE
data with standard terminologies, AERS-DM could be a
platform for deeper mining by further connecting with
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http://www.jbiomedsem.com/content/5/1/36clinical notes, scientific literature, gene expression, pro-
teomics and pharmacogenomics data, and various other
ontologies. We believe that AERS-DM could be used to
explore the complex network among drugs and ADEs,
and such research would bear far-reaching significance in
terms of the study paradigm of ADEs.
Limitations
We used only two drug ontologies (RxNorm and NDF-RT)
and one ADE terminology (MedDRA) to normalize and ag-
gregate AERS data. We believe additional investigations of
other standard terminologies, such as SNOMED-CT would
be beneficial in exploring the potential of standardized
AERS reporting data in data mining.
Conclusion
In this study, we leveraged three biomedical ontologies―Rx-
Norm, NDF-RT, and MedDRA―for normalizing and aggre-
gating the AERS data and produced a standardized ADE
dataset referred to as AERS-DM. With the normalized
codes and aggregated features, the AERS-DM would be use-
ful for the research community in the data mining field. We
will continue to refine and optimize the AERS-DM and up-
date it periodically in the future. In addition, we will investi-
gate the integration of the AERS-DM data set with other
health data sources, such as EHR data, literature databases
(e.g., Semantic Medline [44]) and other ontologies (e.g.,
Drug Ontology [45]), for the purpose of promoting ADE
detection in individual drugs. Finally, we will leverage
SNOMED-CT for standardizing the AERS data.
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